CoChat

ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer

Open access
Li, Qiang, Damish, Alexis W., Frazier, Zoë, Liu, David, Reznichenko, Elizaveta, Kamburov, Atanas, Bell, Andrew, Zhao, Huiyong, Jordan, Emmet J., Gao, S. Paul, Ma, Jennifer, Abbosh, Philip H., Bellmunt, Joaquim, Plimack, Elizabeth R., Lazaro, Jean-Bernard, Solit, David B., Bajorin, Dean, Rosenberg, Jonathan E., D'Andrea, Alan D., Riaz, Nadeem, Van Allen, Eliezer M., Iyer, Gopa, Mouw, Kent W. · 2019 · Clinical Cancer Research
Cited by 159

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Purpose: DNA-damaging agents comprise the backbone of systemic treatment for many tumor types; however, few reliable predictive biomarkers are available to guide use of these agents. In muscle-invasive bladder cancer (MIBC), cisplatin-based chemotherapy improves survival, yet response varies widely among patients. Here, we sought to define the role of the nucleotide excision repair (NER) gene ERCC2 as a biomarker predictive of response to cisplatin in MIBC. Experimental Design: Somatic missense mutations in ERCC2 are associated with improved response to cisplatin-based chemotherapy; however, clinically identified ERCC2 mutations are distributed throughout the gene, and the impact of individual ERCC2 variants on NER capacity and cisplatin sensitivity is unknown. We developed a microscopy-based NER assay to profile ERCC2 mutations observed retrospectively in prior studies and prospectively within the context of an institution-wide tumor profiling initiative. In addition, we created the first ERCC2-deficient bladder cancer preclinical model for studying the impact of ERCC2 loss of function. Results: We used our functional assay to test the NER capacity of clinically observed ERCC2 mutations and found that most ERCC2 helicase domain mutations cannot support NER. Furthermore, we show that introducing an ERCC2 mutation into a bladder cancer cell line abrogates NER activity and is sufficient to drive cisplatin sensitivity in an orthotopic xenograft model. Conclusions: Our data support a direct role for ERCC2 mutations in driving cisplatin response, define the functional landscape of ERCC2 mutations in bladder cancer, and provide an opportunity to apply combined genomic and functional approaches to prospectively guide therapy decisions in bladder cancer. See related commentary by Grivas, p. 907

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-18-1001

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 159

Metadata

Authors
Li, Q., Damish, A. W., Frazier, Z., Liu, D., Reznichenko, E., Kamburov, A., Bell, A., Zhao, H., Jordan, E. J., Gao, S. P., Ma, J., Abbosh, P. H., Bellmunt, J., Plimack, E. R., Lazaro, J.-B., Solit, D. B., Bajorin, D., Rosenberg, J. E., D'Andrea, A. D., Riaz, N., Van Allen, E. M., Iyer, G., & Mouw, K. W.
Venue
Clinical Cancer Research
Published
2019-02-01
Volume
25
Issue
3
Pages
977-988
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2834512504
Cited by
159
References
6
FWCI
13.67
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-18-1001
The paper
Li, Q., Damish, A. W., Frazier, Z., Liu, D., Reznichenko, E., Kamburov, A., Bell, A., Zhao, H., Jordan, E. J., Gao, S. P., Ma, J., Abbosh, P. H., Bellmunt, J., Plimack, E. R., Lazaro, J.-B., Solit, D. B., Bajorin, D., Rosenberg, J. E., D'Andrea, A. D., . . . Mouw, K. W. (2019). ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-18-1001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.